Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Transitional cell carcinoma of bladder
0.420 GeneticVariation BEFREE The BRAF and KRAS gene mutations were never described before in pediatric UC. 31620413

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Transitional cell carcinoma of bladder
0.420 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Transitional cell carcinoma of bladder
0.420 GeneticVariation BEFREE K-RAS mutation in transitional cell carcinoma of urinary bladder. 12092657

2001

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Transitional cell carcinoma of bladder
0.420 CausalMutation CGI

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
Transitional cell carcinoma of bladder
0.420 Biomarker HPO

Entrez Id: 613
Gene Symbol: BCR
BCR
Transitional cell carcinoma of bladder
0.300 GeneticVariation UNIPROT

Entrez Id: 2321
Gene Symbol: FLT1
FLT1
Transitional cell carcinoma of bladder
0.300 GeneticVariation UNIPROT

Entrez Id: 5979
Gene Symbol: RET
RET
Transitional cell carcinoma of bladder
0.300 GeneticVariation UNIPROT

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 Biomarker BEFREE CHK1 and p53 demonstrated a positive correlation in BUC, and both were positively associated with the histological grade, clinical pathological staging, lymphatic metastasis and the 5-year survival rate (P<0.05). 29391889

2018

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
Transitional cell carcinoma of bladder
0.200 AlteredExpression BEFREE Therefore, the evaluation of EGFR and HER-2 expression in BTCC may contribute to identifying patients who are at increased risk of disease progression and recurrence. 30296252

2018

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 GeneticVariation BEFREE Two bladder urothelial carcinoma cell lines were used: RT4 (wild-type TP53 gene) and T24 (mutated TP53 gene). 28229968

2017

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 Biomarker BEFREE A comparative gene set enrichment analysis of tumor and adjacent normal tissues suggested BUC tumorigenesis resulted mainly from enrichment of cell cycle and DNA damage and repair-related biological processes and pathways, including TP53 and mitotic recombination. 28356754

2017

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 GeneticVariation BEFREE Deletion/duplication mutation screening of TP53 gene in patients with transitional cell carcinoma of urinary bladder using multiplex ligation-dependent probe amplification. 26685928

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
Transitional cell carcinoma of bladder
0.200 Biomarker BEFREE HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. 27034533

2016

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
Transitional cell carcinoma of bladder
0.200 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 AlteredExpression BEFREE BAI‑1 may be involved in the negative regulation of BTCC microvascular proliferation, and its expression may be associated with a reduction in p53 mutations. 26129954

2015

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 Biomarker BEFREE Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. 21388952

2011

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 GeneticVariation BEFREE Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study. 18367096

2009

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 GeneticVariation BEFREE MDM2 SNP309 and p53 Arg72Pro polymorphisms might influence the clinical outcome of TCCB in a distinctive way between superficial TCCB and invasive TCCB. 18575717

2008

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 Biomarker BEFREE Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. 18645275

2008

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 GeneticVariation BEFREE TGF-betaRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 alterations are not associated with microsatellite instability or p53 mutations in invasive urothelial carcinoma of the urinary bladder. 17676485

2007

Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
Transitional cell carcinoma of bladder
0.200 AlteredExpression BEFREE Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. 17987577

2007

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 GeneticVariation BEFREE To address to the question whether promoter methylation of novel p53 effector genes is a common event in transitional cell carcinoma of the bladder, we selected the p53 target genes apoptotic protein-activating factor (APAF-1), Caspase 8 (CASP-8), death-associated protein kinase, (DAPK-1) and insulin-like growth-factor-binding protein-3 (IGFBP-3), performing quantitative methylation-specific real-time PCR. 16642478

2006

Entrez Id: 7157
Gene Symbol: TP53
TP53
Transitional cell carcinoma of bladder
0.200 Biomarker BEFREE Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications. 15816547

2005